Literature DB >> 24396674

Characteristics of acromegaly in Korea with a literature review.

Jae Won Hong1, Cheol Ryong Ku1, Sun Ho Kim2, Eun Jig Lee1.   

Abstract

Acromegaly is a slowly progressive disease caused by excessive growth hormone (GH), which is related to a GH secreting pituitary tumor in most cases. Herein, we describe the epidemiology, clinical characteristics, and treatment of acromegaly in Korea with a literature review. The average annual incidence of acromegaly in Korea was 3.9 cases per million people, which was within the range of previous Western studies. The primary treatment for acromegaly was also transsphenoidal adenomectomy, which accounted for 90.4% of patients whose primary therapeutic options were known. The overall surgical remission rates were 89%, 87%, 64%, 70%, and 50% for modified Hardy classification I, II, IIIA, IIIB, and IV, respectively. An updated and larger study regarding the treatment outcome of medical/radiotherapy in Korean acromegalic patients is needed.

Entities:  

Keywords:  Acromegaly; Growth hormone; Pituitary neoplasms

Year:  2013        PMID: 24396674      PMCID: PMC3811698          DOI: 10.3803/EnM.2013.28.3.164

Source DB:  PubMed          Journal:  Endocrinol Metab (Seoul)        ISSN: 2093-596X


  27 in total

1.  Radiotherapy in acromegaly: the argument against.

Authors:  Ariel L Barkan
Journal:  Clin Endocrinol (Oxf)       Date:  2003-02       Impact factor: 3.478

Review 2.  Cardiovascular function in acromegaly.

Authors:  R N Clayton
Journal:  Endocr Rev       Date:  2003-06       Impact factor: 19.871

Review 3.  Acromegaly and the cardiovascular system.

Authors:  Gaetano Lombardi; Mariano Galdiero; Renata S Auriemma; Rosario Pivonello; Annamaria Colao
Journal:  Neuroendocrinology       Date:  2006       Impact factor: 4.914

4.  Colonoscopic screening and follow-up in patients with acromegaly: a multicenter study in Italy.

Authors:  Massimo Terzolo; Giuseppe Reimondo; Maurizio Gasperi; Renato Cozzi; Rosario Pivonello; Giovanni Vitale; Alfredo Scillitani; Roberto Attanasio; Elisabetta Cecconi; Fulvia Daffara; Ezio Gaia; Ennio Martino; Gaetano Lombardi; Alberto Angeli; Annamaria Colao
Journal:  J Clin Endocrinol Metab       Date:  2004-10-26       Impact factor: 5.958

Review 5.  Epidemiology of acromegaly.

Authors:  I M Holdaway; C Rajasoorya
Journal:  Pituitary       Date:  1999-06       Impact factor: 4.107

Review 6.  Place of cabergoline in acromegaly: a meta-analysis.

Authors:  Laure Sandret; Patrick Maison; Philippe Chanson
Journal:  J Clin Endocrinol Metab       Date:  2011-02-16       Impact factor: 5.958

Review 7.  Acromegaly: re-thinking the cancer risk.

Authors:  Siobhan Loeper; Shereen Ezzat
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

8.  Early vascular alterations in acromegaly.

Authors:  Gregorio Brevetti; Paolo Marzullo; Antonio Silvestro; Rosario Pivonello; Gabriella Oliva; Carolina di Somma; Gaetano Lombardi; Annamaria Colao
Journal:  J Clin Endocrinol Metab       Date:  2002-07       Impact factor: 5.958

9.  Determinants of clinical outcome and survival in acromegaly.

Authors:  C Rajasoorya; I M Holdaway; P Wrightson; D J Scott; H K Ibbertson
Journal:  Clin Endocrinol (Oxf)       Date:  1994-07       Impact factor: 3.478

10.  Mortality in acromegaly: a metaanalysis.

Authors:  O M Dekkers; N R Biermasz; A M Pereira; J A Romijn; J P Vandenbroucke
Journal:  J Clin Endocrinol Metab       Date:  2007-10-30       Impact factor: 5.958

View more
  9 in total

1.  Rater Reliability of the Hardy Classification for Pituitary Adenomas in the Magnetic Resonance Imaging Era.

Authors:  Michael A Mooney; Douglas A Hardesty; John P Sheehy; C Roger Bird; Kristina Chapple; William L White; Andrew S Little
Journal:  J Neurol Surg B Skull Base       Date:  2017-06-07

2.  Change in quality of life in patients with acromegaly after treatment with octreotide LAR: first application of AcroQoL in Korea.

Authors:  Sang Ouk Chin; Choon Hee Chung; Yoon-Sok Chung; Byung-Joon Kim; Hee Young Kim; In-Ju Kim; Jung Guk Kim; Min-Seon Kim; Seong-Yeon Kim; Eun Jig Lee; Ki Young Lee; Sung-Woon Kim
Journal:  BMJ Open       Date:  2015-06-10       Impact factor: 2.692

Review 3.  Precision Therapy in Acromegaly Caused by Pituitary Tumors: How Close Is It to Reality?

Authors:  Cheol Ryong Ku; Vladimir Melnikov; Zhaoyun Zhang; Eun Jig Lee
Journal:  Endocrinol Metab (Seoul)       Date:  2020-06-24

4.  Patient Characteristics, Diagnostic Delays, Treatment Patterns, Treatment Outcomes, Comorbidities, and Treatment Costs of Acromegaly in China: A Nationwide Study.

Authors:  Xiaopeng Guo; Kailu Wang; Siyue Yu; Lu Gao; Zihao Wang; Huijuan Zhu; Bing Xing; Shuyang Zhang; Dong Dong
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-01       Impact factor: 5.555

5.  Malaysian Consensus Statement for the Diagnosis and Management of Acromegaly.

Authors:  Zanariah Hussein; Mohamed Long Bidin; Azmi Alias; Muthukkumaran Thiagarajan; Kartikasalwah Abdul Latif; Jeyakantha Ratnasingam; Wan Juani Wan Seman; Azraai Nasruddin
Journal:  J ASEAN Fed Endocr Soc       Date:  2019-05-28

6.  Let's focus more on regional diversity of acromegaly.

Authors:  Sylvère Störmann
Journal:  Ann Transl Med       Date:  2022-08

7.  Brief review of articles in 'endocrinology and metabolism' in 2013.

Authors:  Won-Young Lee
Journal:  Endocrinol Metab (Seoul)       Date:  2014-09

8.  Incidence and prevalence of acromegaly in a large US health plan database.

Authors:  Tanya Burton; Elisabeth Le Nestour; Maureen Neary; William H Ludlam
Journal:  Pituitary       Date:  2016-06       Impact factor: 4.107

9.  [Selective screening of patients with associated somatic diseases as a method of early detection of acromegaly].

Authors:  M B Antsiferov; V S Pronin; T M Alekseeva; O A Ionova; E Y Martynova; Yu E Poteshkin; N A Chubrova; K Y Zherebchikova
Journal:  Probl Endokrinol (Mosk)       Date:  2021-01-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.